Form 4: Vaxart Director Kevin Finney Acquires Shares and Stock Options
SEC Form 4 Filing
Vaxart director Kevin Finney acquired 32,000 shares of common stock and 190,800 stock options on January 28, 2025, as part of his compensation.
Summary
- Kevin Finney, a director at Vaxart, Inc., acquired 32,000 shares of common stock on January 28, 2025.
- These shares were granted upon the vesting of restricted stock units.
- Additionally, Mr. Finney acquired 190,800 stock options with an exercise price of $0.7522 on the same date.
- The stock options vest annually over three years from January 28, 2025, and expire on January 28, 2035.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed as a neutral to slightly positive event as it aligns interests. There is no indication of any negative sentiment.
Positives
- The acquisition of shares and stock options aligns the director's interests with those of the shareholders.
- The vesting schedule of the stock options encourages long-term commitment from the director.
Industry Context
This is a standard SEC Form 4 filing, which is common for directors and officers of publicly traded companies when they acquire or dispose of company securities. It is a routine part of corporate governance and transparency.
Comparison to Industry Standards
- The vesting schedule of the stock options is typical for director compensation packages in the biotechnology industry.
- The use of restricted stock units and stock options is a common practice to align the interests of directors with the long-term performance of the company.
- Similar filings are made by directors and officers of comparable companies such as Moderna, BioNTech, and Novavax when they receive equity compensation.
Stakeholder Impact
- The acquisition of shares and stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution of the Power of Attorney by Kevin P. Finney. |
| 01/28/2025 | Date of the transaction where Kevin Finney acquired shares and stock options. |
| 01/29/2025 | Date of signature of the Form 4 filing. |
| 01/28/2035 | Expiration date of the stock options. |
Keywords
Vaxart, Director, Kevin Finney, Stock Options, Share Acquisition, Restricted Stock Units, Insider Trading, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.